Scholarlink

<p>Alzheimer’s disease is a neurodegenerative disease that is usually detected at a late stage when it is no longer possible to treat the disease, only its symptoms; since diagnosis is&#xa0;currently difficult at an early stage. However, the progression of the disease can be slowed down&#xa0;with available treatment methods if diagnosed at an early stage. Alzheimer’s disease significantly reduces the quality of life for both the patient and their family. Amyloid beta (Aβ) protein 42 (Aβ42) is one of the main biomarkers widely used for the diagnosis of Alzheimer’s disease. Rapid, sensitive and reliable biosensors have become a focus of interest for researchers to be able to provide early-stage detection and treatment window for better therapy response. Here, we commented on electrochemical biosensors that can reliably detect Aβ42 protein in different biological/clinical samples, and demonstrated their success in the early diagnosis of Alzheimer’s disease, and addressed the need for further research on electrochemical&#xa0;biosensors for the early diagnosis of this disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Success of electrochemical biosensors developed for the determination of amyloid-beta 42 (Aβ42) protein in the diagnosis of Alzheimer’s disease

  • 期刊论文

  • 发表日期：

    2025年7月24日

查看全文
  • Oguz Özbek,
  • Isa Mert Eski,
  • Caglar Berkel

摘要

Alzheimer’s disease is a neurodegenerative disease that is usually detected at a late stage when it is no longer possible to treat the disease, only its symptoms; since diagnosis is currently difficult at an early stage. However, the progression of the disease can be slowed down with available treatment methods if diagnosed at an early stage. Alzheimer’s disease significantly reduces the quality of life for both the patient and their family. Amyloid beta (Aβ) protein 42 (Aβ42) is one of the main biomarkers widely used for the diagnosis of Alzheimer’s disease. Rapid, sensitive and reliable biosensors have become a focus of interest for researchers to be able to provide early-stage detection and treatment window for better therapy response. Here, we commented on electrochemical biosensors that can reliably detect Aβ42 protein in different biological/clinical samples, and demonstrated their success in the early diagnosis of Alzheimer’s disease, and addressed the need for further research on electrochemical biosensors for the early diagnosis of this disease.